|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for GSTA4 |
 Gene summary |
| Basic gene Info. | Gene symbol | GSTA4 |
| Gene name | glutathione S-transferase alpha 4 | |
| Synonyms | GSTA4-4|GTA4 | |
| Cytomap | UCSC genome browser: 6p12.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001512.3, | |
| Description | GST class-alpha member 4S-(hydroxyalkyl)glutathione lyase A4glutathione S-alkyltransferase A4glutathione S-aralkyltransferase A4glutathione S-aryltransferase A4glutathione S-transferase A4glutathione S-transferase A4-4glutathione transferase A4-4 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605450 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000170899 | ||
| HPRD : 06899 | ||
| Vega : OTTHUMG00000014868 | ||
| Protein | UniProt: O15217 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_GSTA4 | |
| BioGPS: 2941 | ||
| Pathway | NCI Pathway Interaction Database: GSTA4 | |
| KEGG: GSTA4 | ||
| REACTOME: GSTA4 | ||
| Pathway Commons: GSTA4 | ||
| Context | iHOP: GSTA4 | |
| ligand binding site mutation search in PubMed: GSTA4 | ||
| UCL Cancer Institute: GSTA4 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006749 | glutathione metabolic process | 10329152 | GO:0006805 | xenobiotic metabolic process | 10329152 |
| Top |
| Ligand binding site mutations for GSTA4 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | Q45 | D46Y | LUAD | 1 | Y217 | V216I | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for GSTA4 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | Y217 | V216I | -1.5287704 | Q45 | D46Y | -0.38622155 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for GSTA4 from PDB |
| Top |
| Differential gene expression and gene-gene network for GSTA4 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for GSTA4 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0030567 | Parkinson Disease | 2 | Biomarker, GeneticVariation |
| umls:C0003850 | Arteriosclerosis | 2 | Biomarker, Therapeutic |
| umls:C0032927 | Precancerous Conditions | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for GSTA4 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|nutraceutical | DB00143 | Glutathione | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of GSTA4 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (GGL,CYS,GLY) | 1gul | A | Q45 | III | Peptide ligand (GGL,CYS,GLY) | 1gul | B | Q45 | III | Peptide ligand (GGL,CYS,GLY) | 1gul | C | Q45 | III | Peptide ligand (GGL,CYS,GLY) | 1gul | D | Q45 | III | Peptide ligand (GGL,CYS,GLY) | 1gul | E | Q45 | III | Peptide ligand (GGL,CYS,GLY) | 1gul | F | Q45 | III | Peptide ligand (GGL,CYS,GLY) | 1gul | G | Q45 | III | Peptide ligand (GGL,CYS,GLY) | 1gul | H | Q45 | BOB | L-GAMMA-GLUTAMYL-S-[(1S,2R)-2-HYDROXY-1-(2-HYDROXYETHYL)HEPTYL]-L-CYSTEINYLGLYCINE | 3ik7 | B | Q45 | BOB | L-GAMMA-GLUTAMYL-S-[(1S,2R)-2-HYDROXY-1-(2-HYDROXYETHYL)HEPTYL]-L-CYSTEINYLGLYCINE | 3ik7 | C | Q45 | BOB | L-GAMMA-GLUTAMYL-S-[(1S,2R)-2-HYDROXY-1-(2-HYDROXYETHYL)HEPTYL]-L-CYSTEINYLGLYCINE | 3ik7 | D | Y217 |
| Top |
| Conservation information for LBS of GSTA4 |
| Multiple alignments for O15217 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |